Biocon’s step-down, wholly-owned subsidiary -- Biocon Generics Inc, has acquired Eywa Pharma Inc’s oral solid dosage manufacturing facility, located in Cranbury, New Jersey, U.S., effective September 01, 2023. The facility is acquired for a total consideration of $7.7 million. As part of the acquisition, the existing workforce of the facility will transition to Biocon Generics Inc. The facility has a potential for capacity expansion up to 2 billion tablets/capsules per year.
The acquisition will also enable it to add oral solid dosage capacities for new products earlier than originally planned and ensure continuity of supply through the diversification of its manufacturing infrastructure.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
